nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Nuvig Therapeutics is a biotechnology company developing treatments for autoimmune diseases that do not rely on immunosuppression.

Autoimmunity BioSolutions develops next-generation immuno-corrective therapies targeting genetically-defined subpopulations of patients with autoimmune diseases.

Valora Therapeutics Inc. is a biotechnology company developing novel immunotherapeutics using its proprietary AbLec platform to modulate glyco-immune checkpoints.

TRexBio is a biotechnology company developing novel therapies for inflammatory diseases using their Deep Biology platform to focus on immune homeostasis.

Leal Therapeutics is a biotechnology company developing treatments for central nervous system disorders, focusing on amyotrophic lateral sclerosis (ALS) and schizophrenia.

Archon Biosciences develops AI-driven Antibody Cages to enhance antibody treatments by improving target engagement and biodistribution.

Axonis Therapeutics is a biotechnology company developing novel neuromedicines targeting neurological disorders like epilepsy and pain.

Passkey Therapeutics develops novel therapies that target rare protein combinations to treat complex diseases like cancer and autoimmune disorders.

Terray Therapeutics integrates ultra-high throughput experimentation with generative AI, biology, medicinal chemistry, automation, and nanotechnology to transform small molecule drug discovery.

858 Therapeutics is a biotechnology company developing small molecule therapeutics for oncology and immunology, with a lead asset, ETX-19477, in Phase 1 trials for advanced solid tumors.

Radiant Biotherapeutics develops innovative therapies using its proprietary Multabody™ platform to target oncology, inflammation, immunology, and infectious diseases.

Ability Biologics is a biotech startup focused on creating next-generation antibody therapeutics for unmet medical needs using their proprietary AI platform, AbiLeap™.

Odyssey Therapeutics is a biotech firm specializing in developing precision immunomodulators and oncology medicines, with plans to advance multiple therapeutic programs into clinical studies.

Seismic Therapeutic is a biotechnology firm specializing in the development of immunology drugs using a machine learning-enabled platform to advance its biologics pipeline through clinical trials.

Alto Neuroscience specializes in precision psychiatry, developing targeted medicines based on its Precision Psychiatry Platform™, which utilizes brain biomarkers to match patients with appropriate treatments.

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Deka Biosciences is a biotech company that aims to improve immunotherapy treatments by combining biology with precision medicine, specifically through their investigational new drug, DK210 (EGFR), which has dissociated IL-2 potency from toxicity.

Arialys Therapeutics is a biotechnology company that develops precision medicines to target pathogenic autoantibodies in the central nervous system, with a focus on treating neuropsychiatric diseases caused by autoimmunity.

ROME Therapeutics is a biotechnology company that develops breakthrough medicines for serious diseases, with a focus on an inhibitor of LINE-1 reverse transcriptase for autoimmune diseases, using their proprietary data science platform to identify active repeat elements and assess their roles in disease.